Inventor · disambiguated record
Leonardo Borras
Also filed as: BORRAS LEONARDO · BORRAS LEONARDO JOSE
28 granted patents·15 pending applications·260 citations·filing 2008–2025
96Inventor score
Top patents by PatentIndex Score
43 records- 0197US9090684B2Stable and soluble antibodies inhibiting VEGFESBATECH ALCON BIOMED RES UNIT·Filed 2012·Granted Jul 28, 2015·54 cites·8 claims
- 0296US8293235B2Humanization of rabbit antibodies using a universal antibody frameworkBORRAS LEONARDO·Filed 2009·Granted Oct 23, 2012·49 cites·16 claims
- 0395US8673310B2Stable and soluble antibodies inhibiting TNFαBORRAS LEONARDO·Filed 2009·Granted Mar 18, 2014·36 cites·12 claims
- 0495US8349322B2Stable and soluble antibodies inhibiting VEGFESBATECH ALCON BIOMED RES UNIT·Filed 2009·Granted Jan 8, 2013·31 cites·10 claims
- 0593US10590193B2Stable and soluble antibodies inhibiting VEGFESBATECH ALCON BIOMED RES UNIT·Filed 2017·Granted Mar 17, 2020·9 cites·14 claims
- 0693US9873737B2Stable and soluble antibodies inhibiting VEGFESBATECH ALCON BIOMED RES UNIT·Filed 2015·Granted Jan 23, 2018·10 cites·7 claims
- 0791US9422366B2Stable and soluble antibodies inhibiting TNF alphaESBATECH ALCON BIOMED RES UNIT·Filed 2013·Granted Aug 23, 2016·12 cites·24 claims
- 0891US8937162B2Humanization of rabbit antibodies using a universal antibody frameworkBORRAS LEONARDO·Filed 2012·Granted Jan 20, 2015·14 cites·8 claims
- 0990US10100111B2Stable and soluble antibodies inhibiting TNF alphaESBATECH ALCON BIOMED RES UNIT·Filed 2016·Granted Oct 16, 2018·7 cites·21 claims
- 1089US10087244B2Humanization of rabbit antibodies using a universal antibody frameworkESBATECH ALCON BIOMED RES UNIT·Filed 2015·Granted Oct 2, 2018·6 cites·2 claims
- 1188US9593161B2Humanization of rabbit antibodies using a universal antibody frameworkESBATECH ALCON BIOMED RES UNIT·Filed 2014·Granted Mar 14, 2017·7 cites·19 claims
- 1287US11912771B2MAGE-A4 peptide-MHC antigen binding proteinsCDR LIFE AG·Filed 2022·Granted Feb 27, 2024·2 cites·30 claims
- 1384US10570198B2Stable and soluble antibodiesNOVARTIS AG·Filed 2016·Granted Feb 25, 2020·3 cites·5 claims
- 1483US8796425B2Method for decreasing immunogenicityURECH DAVID·Filed 2010·Granted Aug 5, 2014·3 cites·3 claims
- 1582US9803027B2Method for decreasing immunogenicityESBATECH ALCON BIOMED RES UNIT·Filed 2014·Granted Oct 31, 2017·2 cites·2 claims
- 1682US8545849B2Stable and soluble antibodiesBORRAS LEONARDO JOSE·Filed 2011·Granted Oct 1, 2013·7 cites·8 claims
- 1780US9556265B2Solubility optimization of immunobindersBORRAS LEONARDO·Filed 2009·Granted Jan 31, 2017·3 cites·5 claims
- 1879US8280711B2Sequence based engineering and optimization of single chain antibodiesURECH DAVID M·Filed 2008·Granted Oct 2, 2012·3 cites·14 claims
- 1977US9598487B2Stable and soluble antibodiesESBATECH ALCON BIOMED RES UNIT·Filed 2013·Granted Mar 21, 2017·2 cites·5 claims
- 2075US2025243266A1Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseasesCDR LIFE AG·Filed 2024·Application pending·0 cites
- 2174US2019382498A1Humanized immunobinders of cell-surface antigensNOVARTIS AG·Filed 2019·Application pending·0 cites
- 2272US12344663B2Anti-C3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseasesCDR LIFE AG·Filed 2022·Granted Jul 1, 2025·0 cites·94 claims
- 2372US11046757B2Solubility optimization of immunobindersNOVARTIS AG·Filed 2019·Granted Jun 29, 2021·0 cites·4 claims
- 2470US2020172608A1Stable and soluble antibodies inhibiting vegfNOVARTIS AG·Filed 2020·Application pending·0 cites
- 2570US2021214461A1Method for decreasing immunogenicityNOVARTIS AG·Filed 2020·Application pending·0 cites
- 2668US11578123B2Stable and soluble antibodies inhibiting TNFαNOVARTIS AG·Filed 2018·Granted Feb 14, 2023·0 cites·17 claims
- 2767US12161673B2MAGE-A4 peptide dual T cell engagersCDR LIFE AG·Filed 2023·Granted Dec 10, 2024·0 cites·40 claims
- 2867US11858981B2Humanization of rabbit antibodies using a universal antibody frameworkNOVARTIS AG·Filed 2017·Granted Jan 2, 2024·0 cites·19 claims
- 2967US2024279344A1Mage-a4 peptide-mhc antigen binding proteinsCDR LIFE AG·Filed 2024·Application pending·0 cites
- 3066US10781268B2Method for decreasing immunogenicityNOVARTIS AG·Filed 2017·Granted Sep 22, 2020·0 cites·5 claims
- 3166US2025144141A1Mage-a4 peptide dual t cell engagersCDR LIFE AG·Filed 2024·Application pending·0 cites
- 3260US2022259296A1Complement c3 antigen binding proteinsBOEHRINGER INGELHEIM INT·Filed 2022·Application pending·0 cites
- 3359US2025382357A1Complement c3 antigen binding proteinsBOEHRINGER INGELHEIM INT·Filed 2025·Application pending·0 cites
- 3457US10221237B2Solubility optimization of immunobindersESBATECH ALCON BIOMED RES UNIT·Filed 2016·Granted Mar 5, 2019·0 cites·11 claims
- 3557US2009074780A1Methods of modifying antibodies, and modified antibodies with improved functional propertiesURECH DAVID·Filed 2008·Application pending·0 cites
- 3657US2025002586A1Dual mhc-targeting t cell engagerCDR LIFE AG·Filed 2024·Application pending·0 cites
- 3753US2020048336A1Stable multiple antigen-binding antibodyNOVARTIS PHARMA AG·Filed 2019·Application pending·0 cites
- 3852US2020024358A1Trispecific antigen binding proteinsCDR LIFE AG·Filed 2019·Application pending·0 cites
- 3951US2020062858A1Trispecific antigen binding proteinsCDR LIFE AG·Filed 2019·Application pending·0 cites
- 4050US9908945B2Sequence based engineering and optimization of single chain antibodiesURECH DAVID·Filed 2008·Granted Mar 6, 2018·0 cites·10 claims
- 4149US2013101586A1Stable multiple antigen-binding antibodyESBATECH A NOVARTIS CO LLC·Filed 2012·Application pending·0 cites
- 4249US2019002551A1Methods of modifying antibodies, and modified antibodies with improved functional propertiesESBATECH ALCON BIOMED RES UNIT·Filed 2017·Application pending·0 cites
- 4348US9938336B2Sequence based engineering and optimization of single chain antibodiesURECH DAVID M·Filed 2012·Granted Apr 10, 2018·0 cites·2 claims
Join the waitlist — get patent alerts
Get an alert when Leonardo Borras files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →